Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Identifieur interne : 000A47 ( Main/Exploration ); précédent : 000A46; suivant : 000A48Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
Auteurs : Andrew D. Zelenetz [États-Unis] ; Jacqueline C. Barrientos [États-Unis] ; Jennifer R. Brown [États-Unis] ; Bertrand Coiffier [France] ; Julio Delgado [Espagne] ; Mikl S Egyed [Hongrie] ; Paolo Ghia [Italie] ; Árpád Illés [Hongrie] ; Wojciech Jurczak [Pologne] ; Paula Marlton [Australie] ; Marco Montillo [Italie] ; Franck Morschhauser [France] ; Alexander S. Pristupa [Russie] ; Tadeusz Robak [Pologne] ; Jeff P. Sharman [États-Unis] ; David Simpson [Nouvelle-Zélande] ; Lukáš Smolej [République tchèque] ; Eugen Tausch [Allemagne] ; Adeboye H. Adewoye [États-Unis] ; Lyndah K. Dreiling [États-Unis] ; Yeonhee Kim [États-Unis] ; Stephan Stilgenbauer [Allemagne] ; Peter Hillmen [Royaume-Uni]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Chlorhydrate de bendamustine (administration et posologie), Femelle, Humains, Leucémie chronique lymphocytaire à cellules B (anatomopathologie), Leucémie chronique lymphocytaire à cellules B (traitement médicamenteux), Mâle, Méthode en double aveugle, Pronostic, Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Purines (administration et posologie), Quinazolinones (administration et posologie), Rituximab (administration et posologie), Récidive tumorale locale (anatomopathologie), Récidive tumorale locale (traitement médicamenteux), Résistance aux médicaments antinéoplasiques (), Stade de la tumeur, Sujet âgé, Taux de survie, Thérapie de rattrapage, Études de suivi.
- MESH :
- administration et posologie : Chlorhydrate de bendamustine, Purines, Quinazolinones, Rituximab.
- anatomopathologie : Leucémie chronique lymphocytaire à cellules B, Récidive tumorale locale.
- traitement médicamenteux : Leucémie chronique lymphocytaire à cellules B, Récidive tumorale locale.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Mâle, Méthode en double aveugle, Pronostic, Résistance aux médicaments antinéoplasiques, Stade de la tumeur, Sujet âgé, Taux de survie, Thérapie de rattrapage, Études de suivi.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bendamustine Hydrochloride (administration & dosage), Double-Blind Method, Drug Resistance, Neoplasm (drug effects), Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy), Leukemia, Lymphocytic, Chronic, B-Cell (pathology), Male, Middle Aged, Neoplasm Recurrence, Local (drug therapy), Neoplasm Recurrence, Local (pathology), Neoplasm Staging, Prognosis, Purines (administration & dosage), Quinazolinones (administration & dosage), Rituximab (administration & dosage), Salvage Therapy, Survival Rate.
- MESH :
- chemical , administration & dosage : Bendamustine Hydrochloride, Purines, Quinazolinones, Rituximab.
- drug effects : Drug Resistance, Neoplasm.
- drug therapy : Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm Recurrence, Local.
- pathology : Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm Recurrence, Local.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adult, Aged, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Salvage Therapy, Survival Rate.
Abstract
Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia. New therapies are needed to improve clinically relevant outcomes in these patients. We assessed the efficacy and safety of adding idelalisib, a first-in-class targeted phosphoinositide-3-kinase δ inhibitor, to bendamustine plus rituximab in this population.
DOI: 10.1016/S1470-2045(16)30671-4
PubMed: 28139405
Affiliations:
- Allemagne, Australie, Espagne, France, Hongrie, Italie, Nouvelle-Zélande, Pologne, Royaume-Uni, Russie, République tchèque, États-Unis
- Bade-Wurtemberg, Californie, Catalogne, District de Tübingen, Hauts-de-France, Lombardie, Massachusetts, Nord-Pas-de-Calais, Oregon, État de New York
- Barcelone, Lille, Milan, Ulm
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001023
- to stream PubMed, to step Curation: 001020
- to stream PubMed, to step Checkpoint: 001020
- to stream Ncbi, to step Merge: 004241
- to stream Ncbi, to step Curation: 004241
- to stream Ncbi, to step Checkpoint: 004241
- to stream Main, to step Merge: 000A42
- to stream Main, to step Curation: 000A47
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.</title><author><name sortKey="Zelenetz, Andrew D" sort="Zelenetz, Andrew D" uniqKey="Zelenetz A" first="Andrew D" last="Zelenetz">Andrew D. Zelenetz</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: zeleneta@mskcc.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Barrientos, Jacqueline C" sort="Barrientos, Jacqueline C" uniqKey="Barrientos J" first="Jacqueline C" last="Barrientos">Jacqueline C. Barrientos</name><affiliation wicri:level="2"><nlm:affiliation>Hofstra Northwell School of Medicine, Hofstra University, New Hyde Park, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hofstra Northwell School of Medicine, Hofstra University, New Hyde Park, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Brown, Jennifer R" sort="Brown, Jennifer R" uniqKey="Brown J" first="Jennifer R" last="Brown">Jennifer R. Brown</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Haematology, Centre Hospitalier Lyon Sud, Pierre-Bénite</wicri:regionArea><wicri:noRegion>Pierre-Bénite</wicri:noRegion><wicri:noRegion>Pierre-Bénite</wicri:noRegion></affiliation></author><author><name sortKey="Delgado, Julio" sort="Delgado, Julio" uniqKey="Delgado J" first="Julio" last="Delgado">Julio Delgado</name><affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, Hospital Clínic, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Haematology, Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Egyed, Mikl S" sort="Egyed, Mikl S" uniqKey="Egyed M" first="Mikl S" last="Egyed">Mikl S Egyed</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Somogy County Kaposi Mór Hospital, Kaposvar, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Haematology, Somogy County Kaposi Mór Hospital, Kaposvar</wicri:regionArea><wicri:noRegion>Kaposvar</wicri:noRegion></affiliation></author><author><name sortKey="Ghia, Paolo" sort="Ghia, Paolo" uniqKey="Ghia P" first="Paolo" last="Ghia">Paolo Ghia</name><affiliation wicri:level="3"><nlm:affiliation>Division of Experimental Oncology and Department of Onco-Haematology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Experimental Oncology and Department of Onco-Haematology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Illes, Arpad" sort="Illes, Arpad" uniqKey="Illes A" first="Árpád" last="Illés">Árpád Illés</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, University of Debrecen, Debrecen, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Haematology, University of Debrecen, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author><author><name sortKey="Jurczak, Wojciech" sort="Jurczak, Wojciech" uniqKey="Jurczak W" first="Wojciech" last="Jurczak">Wojciech Jurczak</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Jagiellonian University, Krakow, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Haematology, Jagiellonian University, Krakow</wicri:regionArea><wicri:noRegion>Krakow</wicri:noRegion></affiliation></author><author><name sortKey="Marlton, Paula" sort="Marlton, Paula" uniqKey="Marlton P" first="Paula" last="Marlton">Paula Marlton</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Princess Alexandra Hospital, University of Queensland, School of Medicine, Brisbane, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology, Princess Alexandra Hospital, University of Queensland, School of Medicine, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Montillo, Marco" sort="Montillo, Marco" uniqKey="Montillo M" first="Marco" last="Montillo">Marco Montillo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Haematology, Niguarda Cancer Center, Niguarda Hospital, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Morschhauser, Franck" sort="Morschhauser, Franck" uniqKey="Morschhauser F" first="Franck" last="Morschhauser">Franck Morschhauser</name><affiliation wicri:level="3"><nlm:affiliation>CHRU Lille, Unité GRITA, Department of Haematology, Université de Lille, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CHRU Lille, Unité GRITA, Department of Haematology, Université de Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Pristupa, Alexander S" sort="Pristupa, Alexander S" uniqKey="Pristupa A" first="Alexander S" last="Pristupa">Alexander S. Pristupa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Ryazan Regional Clinical Hospital, Ryazan, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Department of Haematology, Ryazan Regional Clinical Hospital, Ryazan</wicri:regionArea><wicri:noRegion>Ryazan</wicri:noRegion></affiliation></author><author><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Haematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz</wicri:regionArea><wicri:noRegion>Lodz</wicri:noRegion></affiliation></author><author><name sortKey="Sharman, Jeff P" sort="Sharman, Jeff P" uniqKey="Sharman J" first="Jeff P" last="Sharman">Jeff P. Sharman</name><affiliation wicri:level="2"><nlm:affiliation>US Oncology Research, Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>US Oncology Research, Willamette Valley Cancer Institute and Research Center, Eugene, OR</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Simpson, David" sort="Simpson, David" uniqKey="Simpson D" first="David" last="Simpson">David Simpson</name><affiliation wicri:level="1"><nlm:affiliation>North Shore Hospital, Takapuna, Auckland, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>North Shore Hospital, Takapuna, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Smolej, Lukas" sort="Smolej, Lukas" uniqKey="Smolej L" first="Lukáš" last="Smolej">Lukáš Smolej</name><affiliation wicri:level="1"><nlm:affiliation>4th Department of Internal Medicine-Haematology, University Hospital and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>4th Department of Internal Medicine-Haematology, University Hospital and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové</wicri:regionArea><wicri:noRegion>Hradec Králové</wicri:noRegion></affiliation></author><author><name sortKey="Tausch, Eugen" sort="Tausch, Eugen" uniqKey="Tausch E" first="Eugen" last="Tausch">Eugen Tausch</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine III, Ulm University, Ulm, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine III, Ulm University, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement></placeName></affiliation></author><author><name sortKey="Adewoye, Adeboye H" sort="Adewoye, Adeboye H" uniqKey="Adewoye A" first="Adeboye H" last="Adewoye">Adeboye H. Adewoye</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dreiling, Lyndah K" sort="Dreiling, Lyndah K" uniqKey="Dreiling L" first="Lyndah K" last="Dreiling">Lyndah K. Dreiling</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Kim, Yeonhee" sort="Kim, Yeonhee" uniqKey="Kim Y" first="Yeonhee" last="Kim">Yeonhee Kim</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Stilgenbauer, Stephan" sort="Stilgenbauer, Stephan" uniqKey="Stilgenbauer S" first="Stephan" last="Stilgenbauer">Stephan Stilgenbauer</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine III, Ulm University, Ulm, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine III, Ulm University, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement></placeName></affiliation></author><author><name sortKey="Hillmen, Peter" sort="Hillmen, Peter" uniqKey="Hillmen P" first="Peter" last="Hillmen">Peter Hillmen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology/Oncology, St James's University Hospital, Leeds, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Haematology/Oncology, St James's University Hospital, Leeds</wicri:regionArea><wicri:noRegion>Leeds</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28139405</idno><idno type="pmid">28139405</idno><idno type="doi">10.1016/S1470-2045(16)30671-4</idno><idno type="wicri:Area/PubMed/Corpus">001023</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001023</idno><idno type="wicri:Area/PubMed/Curation">001020</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001020</idno><idno type="wicri:Area/PubMed/Checkpoint">001020</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001020</idno><idno type="wicri:Area/Ncbi/Merge">004241</idno><idno type="wicri:Area/Ncbi/Curation">004241</idno><idno type="wicri:Area/Ncbi/Checkpoint">004241</idno><idno type="wicri:Area/Main/Merge">000A42</idno><idno type="wicri:Area/Main/Curation">000A47</idno><idno type="wicri:Area/Main/Exploration">000A47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.</title><author><name sortKey="Zelenetz, Andrew D" sort="Zelenetz, Andrew D" uniqKey="Zelenetz A" first="Andrew D" last="Zelenetz">Andrew D. Zelenetz</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: zeleneta@mskcc.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Barrientos, Jacqueline C" sort="Barrientos, Jacqueline C" uniqKey="Barrientos J" first="Jacqueline C" last="Barrientos">Jacqueline C. Barrientos</name><affiliation wicri:level="2"><nlm:affiliation>Hofstra Northwell School of Medicine, Hofstra University, New Hyde Park, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Hofstra Northwell School of Medicine, Hofstra University, New Hyde Park, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Brown, Jennifer R" sort="Brown, Jennifer R" uniqKey="Brown J" first="Jennifer R" last="Brown">Jennifer R. Brown</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Haematology, Centre Hospitalier Lyon Sud, Pierre-Bénite</wicri:regionArea><wicri:noRegion>Pierre-Bénite</wicri:noRegion><wicri:noRegion>Pierre-Bénite</wicri:noRegion></affiliation></author><author><name sortKey="Delgado, Julio" sort="Delgado, Julio" uniqKey="Delgado J" first="Julio" last="Delgado">Julio Delgado</name><affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, Hospital Clínic, Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Haematology, Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Egyed, Mikl S" sort="Egyed, Mikl S" uniqKey="Egyed M" first="Mikl S" last="Egyed">Mikl S Egyed</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Somogy County Kaposi Mór Hospital, Kaposvar, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Haematology, Somogy County Kaposi Mór Hospital, Kaposvar</wicri:regionArea><wicri:noRegion>Kaposvar</wicri:noRegion></affiliation></author><author><name sortKey="Ghia, Paolo" sort="Ghia, Paolo" uniqKey="Ghia P" first="Paolo" last="Ghia">Paolo Ghia</name><affiliation wicri:level="3"><nlm:affiliation>Division of Experimental Oncology and Department of Onco-Haematology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Experimental Oncology and Department of Onco-Haematology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Illes, Arpad" sort="Illes, Arpad" uniqKey="Illes A" first="Árpád" last="Illés">Árpád Illés</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, University of Debrecen, Debrecen, Hungary.</nlm:affiliation><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Haematology, University of Debrecen, Debrecen</wicri:regionArea><wicri:noRegion>Debrecen</wicri:noRegion></affiliation></author><author><name sortKey="Jurczak, Wojciech" sort="Jurczak, Wojciech" uniqKey="Jurczak W" first="Wojciech" last="Jurczak">Wojciech Jurczak</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Jagiellonian University, Krakow, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Haematology, Jagiellonian University, Krakow</wicri:regionArea><wicri:noRegion>Krakow</wicri:noRegion></affiliation></author><author><name sortKey="Marlton, Paula" sort="Marlton, Paula" uniqKey="Marlton P" first="Paula" last="Marlton">Paula Marlton</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Princess Alexandra Hospital, University of Queensland, School of Medicine, Brisbane, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Haematology, Princess Alexandra Hospital, University of Queensland, School of Medicine, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Montillo, Marco" sort="Montillo, Marco" uniqKey="Montillo M" first="Marco" last="Montillo">Marco Montillo</name><affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Haematology, Niguarda Cancer Center, Niguarda Hospital, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Morschhauser, Franck" sort="Morschhauser, Franck" uniqKey="Morschhauser F" first="Franck" last="Morschhauser">Franck Morschhauser</name><affiliation wicri:level="3"><nlm:affiliation>CHRU Lille, Unité GRITA, Department of Haematology, Université de Lille, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CHRU Lille, Unité GRITA, Department of Haematology, Université de Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Pristupa, Alexander S" sort="Pristupa, Alexander S" uniqKey="Pristupa A" first="Alexander S" last="Pristupa">Alexander S. Pristupa</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Ryazan Regional Clinical Hospital, Ryazan, Russia.</nlm:affiliation><country xml:lang="fr">Russie</country><wicri:regionArea>Department of Haematology, Ryazan Regional Clinical Hospital, Ryazan</wicri:regionArea><wicri:noRegion>Ryazan</wicri:noRegion></affiliation></author><author><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Haematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz</wicri:regionArea><wicri:noRegion>Lodz</wicri:noRegion></affiliation></author><author><name sortKey="Sharman, Jeff P" sort="Sharman, Jeff P" uniqKey="Sharman J" first="Jeff P" last="Sharman">Jeff P. Sharman</name><affiliation wicri:level="2"><nlm:affiliation>US Oncology Research, Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>US Oncology Research, Willamette Valley Cancer Institute and Research Center, Eugene, OR</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Simpson, David" sort="Simpson, David" uniqKey="Simpson D" first="David" last="Simpson">David Simpson</name><affiliation wicri:level="1"><nlm:affiliation>North Shore Hospital, Takapuna, Auckland, New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>North Shore Hospital, Takapuna, Auckland</wicri:regionArea><wicri:noRegion>Auckland</wicri:noRegion></affiliation></author><author><name sortKey="Smolej, Lukas" sort="Smolej, Lukas" uniqKey="Smolej L" first="Lukáš" last="Smolej">Lukáš Smolej</name><affiliation wicri:level="1"><nlm:affiliation>4th Department of Internal Medicine-Haematology, University Hospital and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>4th Department of Internal Medicine-Haematology, University Hospital and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové</wicri:regionArea><wicri:noRegion>Hradec Králové</wicri:noRegion></affiliation></author><author><name sortKey="Tausch, Eugen" sort="Tausch, Eugen" uniqKey="Tausch E" first="Eugen" last="Tausch">Eugen Tausch</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine III, Ulm University, Ulm, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine III, Ulm University, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement></placeName></affiliation></author><author><name sortKey="Adewoye, Adeboye H" sort="Adewoye, Adeboye H" uniqKey="Adewoye A" first="Adeboye H" last="Adewoye">Adeboye H. Adewoye</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dreiling, Lyndah K" sort="Dreiling, Lyndah K" uniqKey="Dreiling L" first="Lyndah K" last="Dreiling">Lyndah K. Dreiling</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Kim, Yeonhee" sort="Kim, Yeonhee" uniqKey="Kim Y" first="Yeonhee" last="Kim">Yeonhee Kim</name><affiliation wicri:level="2"><nlm:affiliation>Gilead Sciences, Foster City, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Gilead Sciences, Foster City, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Stilgenbauer, Stephan" sort="Stilgenbauer, Stephan" uniqKey="Stilgenbauer S" first="Stephan" last="Stilgenbauer">Stephan Stilgenbauer</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine III, Ulm University, Ulm, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine III, Ulm University, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement></placeName></affiliation></author><author><name sortKey="Hillmen, Peter" sort="Hillmen, Peter" uniqKey="Hillmen P" first="Peter" last="Hillmen">Peter Hillmen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Haematology/Oncology, St James's University Hospital, Leeds, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Haematology/Oncology, St James's University Hospital, Leeds</wicri:regionArea><wicri:noRegion>Leeds</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Bendamustine Hydrochloride (administration & dosage)</term><term>Double-Blind Method</term><term>Drug Resistance, Neoplasm (drug effects)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (pathology)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (drug therapy)</term><term>Neoplasm Recurrence, Local (pathology)</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Purines (administration & dosage)</term><term>Quinazolinones (administration & dosage)</term><term>Rituximab (administration & dosage)</term><term>Salvage Therapy</term><term>Survival Rate</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Chlorhydrate de bendamustine (administration et posologie)</term><term>Femelle</term><term>Humains</term><term>Leucémie chronique lymphocytaire à cellules B (anatomopathologie)</term><term>Leucémie chronique lymphocytaire à cellules B (traitement médicamenteux)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Pronostic</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Purines (administration et posologie)</term><term>Quinazolinones (administration et posologie)</term><term>Rituximab (administration et posologie)</term><term>Récidive tumorale locale (anatomopathologie)</term><term>Récidive tumorale locale (traitement médicamenteux)</term><term>Résistance aux médicaments antinéoplasiques ()</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Taux de survie</term><term>Thérapie de rattrapage</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bendamustine Hydrochloride</term><term>Purines</term><term>Quinazolinones</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Chlorhydrate de bendamustine</term><term>Purines</term><term>Quinazolinones</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term><term>Récidive tumorale locale</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Drug Resistance, Neoplasm</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term><term>Récidive tumorale locale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Salvage Therapy</term><term>Survival Rate</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Pronostic</term><term>Résistance aux médicaments antinéoplasiques</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Taux de survie</term><term>Thérapie de rattrapage</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia. New therapies are needed to improve clinically relevant outcomes in these patients. We assessed the efficacy and safety of adding idelalisib, a first-in-class targeted phosphoinositide-3-kinase δ inhibitor, to bendamustine plus rituximab in this population.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Espagne</li><li>France</li><li>Hongrie</li><li>Italie</li><li>Nouvelle-Zélande</li><li>Pologne</li><li>Royaume-Uni</li><li>Russie</li><li>République tchèque</li><li>États-Unis</li></country><region><li>Bade-Wurtemberg</li><li>Californie</li><li>Catalogne</li><li>District de Tübingen</li><li>Hauts-de-France</li><li>Lombardie</li><li>Massachusetts</li><li>Nord-Pas-de-Calais</li><li>Oregon</li><li>État de New York</li></region><settlement><li>Barcelone</li><li>Lille</li><li>Milan</li><li>Ulm</li></settlement></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Zelenetz, Andrew D" sort="Zelenetz, Andrew D" uniqKey="Zelenetz A" first="Andrew D" last="Zelenetz">Andrew D. Zelenetz</name></region><name sortKey="Adewoye, Adeboye H" sort="Adewoye, Adeboye H" uniqKey="Adewoye A" first="Adeboye H" last="Adewoye">Adeboye H. Adewoye</name><name sortKey="Barrientos, Jacqueline C" sort="Barrientos, Jacqueline C" uniqKey="Barrientos J" first="Jacqueline C" last="Barrientos">Jacqueline C. Barrientos</name><name sortKey="Brown, Jennifer R" sort="Brown, Jennifer R" uniqKey="Brown J" first="Jennifer R" last="Brown">Jennifer R. Brown</name><name sortKey="Dreiling, Lyndah K" sort="Dreiling, Lyndah K" uniqKey="Dreiling L" first="Lyndah K" last="Dreiling">Lyndah K. Dreiling</name><name sortKey="Kim, Yeonhee" sort="Kim, Yeonhee" uniqKey="Kim Y" first="Yeonhee" last="Kim">Yeonhee Kim</name><name sortKey="Sharman, Jeff P" sort="Sharman, Jeff P" uniqKey="Sharman J" first="Jeff P" last="Sharman">Jeff P. Sharman</name></country><country name="France"><noRegion><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name></noRegion><name sortKey="Morschhauser, Franck" sort="Morschhauser, Franck" uniqKey="Morschhauser F" first="Franck" last="Morschhauser">Franck Morschhauser</name></country><country name="Espagne"><region name="Catalogne"><name sortKey="Delgado, Julio" sort="Delgado, Julio" uniqKey="Delgado J" first="Julio" last="Delgado">Julio Delgado</name></region></country><country name="Hongrie"><noRegion><name sortKey="Egyed, Mikl S" sort="Egyed, Mikl S" uniqKey="Egyed M" first="Mikl S" last="Egyed">Mikl S Egyed</name></noRegion><name sortKey="Illes, Arpad" sort="Illes, Arpad" uniqKey="Illes A" first="Árpád" last="Illés">Árpád Illés</name></country><country name="Italie"><region name="Lombardie"><name sortKey="Ghia, Paolo" sort="Ghia, Paolo" uniqKey="Ghia P" first="Paolo" last="Ghia">Paolo Ghia</name></region><name sortKey="Montillo, Marco" sort="Montillo, Marco" uniqKey="Montillo M" first="Marco" last="Montillo">Marco Montillo</name></country><country name="Pologne"><noRegion><name sortKey="Jurczak, Wojciech" sort="Jurczak, Wojciech" uniqKey="Jurczak W" first="Wojciech" last="Jurczak">Wojciech Jurczak</name></noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></country><country name="Australie"><noRegion><name sortKey="Marlton, Paula" sort="Marlton, Paula" uniqKey="Marlton P" first="Paula" last="Marlton">Paula Marlton</name></noRegion></country><country name="Russie"><noRegion><name sortKey="Pristupa, Alexander S" sort="Pristupa, Alexander S" uniqKey="Pristupa A" first="Alexander S" last="Pristupa">Alexander S. Pristupa</name></noRegion></country><country name="Nouvelle-Zélande"><noRegion><name sortKey="Simpson, David" sort="Simpson, David" uniqKey="Simpson D" first="David" last="Simpson">David Simpson</name></noRegion></country><country name="République tchèque"><noRegion><name sortKey="Smolej, Lukas" sort="Smolej, Lukas" uniqKey="Smolej L" first="Lukáš" last="Smolej">Lukáš Smolej</name></noRegion></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Tausch, Eugen" sort="Tausch, Eugen" uniqKey="Tausch E" first="Eugen" last="Tausch">Eugen Tausch</name></region><name sortKey="Stilgenbauer, Stephan" sort="Stilgenbauer, Stephan" uniqKey="Stilgenbauer S" first="Stephan" last="Stilgenbauer">Stephan Stilgenbauer</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Hillmen, Peter" sort="Hillmen, Peter" uniqKey="Hillmen P" first="Peter" last="Hillmen">Peter Hillmen</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28139405
|texte= Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28139405" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |